Trial intelligence / Profile preview

Phase 3 study of tanezumab added to diclofenac SR in osteoarthritis of the knee or hip

2009-009318-41Phase 3Completed

Sponsor
Pfizer
Start
Apr 2009
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of tanezumab in knee osteoarthritis (OA) and hip osteoarthritis, sponsored by Pfizer. Started Apr 2009; status: completed.

02

Drugs

tanezumab
03

Conditions

knee osteoarthritis (OA)hip osteoarthritis

Beyond the preview

Go deeper on 2009-009318-41.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-009318-41.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call